ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 microspheres® in unresectable Hepatocellular Cancer
HALIFAX, NS, Nov. 19, 2024 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, has received